For how we live.
The Global Burden of Disease estimates for anxiety disorders separate two things that public debate keeps merging: how many people have it, and how likely a given person is to. Diagnosis is a third question again.
The TAME trial randomised 276 adults with diagnosed anxiety disorders to mindfulness-based stress reduction or escitalopram. The difference on the primary measure was 0.07 points, inside the noninferiority margin.
The pooled effect on self-reported stress was g = -0.35 from 785 participants. The authors of the meta-analysis warn against a miscalibration between the hype and the evidence — their phrase, not ours.